Immune to Cancer: The CRI Blog
-
Cemiplimab Becomes First Treatment Approved for Advanced Cutaneous Squamous Cell Carcinoma
Immunotherapy is now approved for patients with advanced forms of the second most common form of skin…
-
CICON18 Preview: Translating Science into Survival
Highlights from the upcoming International Cancer Immunotherapy Conference (CICON18), including regulating T cell response, tackling the tumor…
-
Recapping the Third Annual Rational Combinations 360°
In September, experts across the immunology and immunotherapy spectrum convened in Philadelphia to discuss the latest advances…
-
CRI-Funded Study Highlights the Importance of Natural Killer Cells in Immunotherapy
CRI scientists Dr. Michele Ardolino and Dr. David Raulet showed that Natural Killer cells can help eliminate…
-
Previewing the 2018 Rational Combinations 360 Conference
The third installment of the Rational Combinations 360 conference, which will be held in Philadelphia September 13-14,…
-
First Immunotherapy Approved for Patients with Small Cell Lung Cancer
Nivolumab (Opdivo®) is now available for patients with metastatic and treatment-resistant small cell lung cancer
-
Living with Small Cell Lung Cancer
Gloria Garcia was diagnosed in 2017 with small cell lung cancer. After combination ipilimumab/nivolumab immunotherapy treatment she…
-
Former CRI Grantee Dr. Lieping Chen Named a “2018 Giant of Cancer Care in Immuno-Oncology”
Dr. Lieping Chen's work helped pave the way for the development of the PD-1/PD-L1 checkpoint immunotherapies that…
-
Running with Bigfoot for Cancer Immunotherapy
Scientist Thomas Tan discusses his preparation for the Bigfoot 100K and his motivation for fundraising for cancer…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.